HomeInsightsStock Comparison

Remus Pharmaceuticals Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Remus Pharmaceuticals Ltd vs Senores Pharmaceuticals Ltd Stock Comparison

Last Updated on: May 17, 2025

Key Highlights

  • The Latest Trading Price of Remus Pharmaceuticals Ltd is ₹ 2207 as of 16 May 15:30.
  • The P/E Ratio of Remus Pharmaceuticals Ltd is 47.2 as of March 2024 .The P/E Ratio of Senores Pharmaceuticals Ltd is 0 as of March 2024.
  • The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024 .The Market Cap of Senores Pharmaceuticals Ltd is ₹ 0 crore as of March 2024.
  • The revenue of Remus Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Senores Pharmaceuticals Ltd for the Mar '25 is ₹ 125.98 crore as compare to the Dec '24 revenue of ₹ 108.18 crore. This represent the growth of 16.45%.
  • The ebitda of Remus Pharmaceuticals Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Senores Pharmaceuticals Ltd for the Mar '25 is ₹ 31.21 crore as compare to the Dec '24 ebitda of ₹ 30.85 crore. This represent the growth of 1.17%.
  • The net profit of Remus Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of 0.0% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 7.11 crore to ₹ 17.97 crore over 4 quarters. This represents a CAGR of 152.74% .
  • The Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 3.5 % on March 2024 . This represents a CAGR of 16.93% over 2 yearsThe Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

PE

Market Cap

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Remus Pharmaceuticals Ltd

  • Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
  • Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
  • It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
  • The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

About Senores Pharmaceuticals Ltd

  • Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
  • Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
  • The Regulated Markets business is focused on Regulated Markets of US and Canada.
  • The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

Remus Pharmaceuticals Ltd News Hub

News

Remus Pharmaceuticals to table results

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 17 M...

Read more

13 May 2025 16:52

News

Board of Remus Pharmaceuticals recommends interim dividend

Remus Pharmaceuticals announced that the Board of Directors of the Company at its meeting ...

Read more

09 Nov 2024 16:57

News

Remus Pharmaceuticals to convene board meeting

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 No...

Read more

07 Nov 2024 10:21

News

Remus Pharmaceuticals to convene AGM

Remus Pharmaceuticals announced that the 9th Annual General Meeting (AGM) of the company w...

Read more

31 Aug 2024 15:40

News

Remus Pharmaceuticals to table results

Remus Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 16 M...

Read more

10 May 2024 12:07

News

Remus Pharmaceuticals schedules EGM

Remus Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Compan...

Read more

24 Apr 2024 10:34

Senores Pharmaceuticals Ltd News Hub

News

Senores Pharmaceuticals to hold board meeting

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 15...

Read more

10 May 2025 11:12

News

Senores Pharmaceuticals Inc. to acquire USFDA approved ANDA for Tramadol Tablets

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

09 May 2025 09:29

News

Senores Pharmaceuticals gains on acquiring Topiramate tablets from Wockhardt

Shares of Wockhardt declined 2.15% to Rs 1,267 on the BSE. The market size of Topiramate t...

Read more

06 May 2025 10:51

News

Senores inks deal to acquire Wockhardt's ANDA for Topiramate

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

05 May 2025 18:55

News

Senores Pharmaceuticals to acquire 14 ANDAs from Dr Reddy's

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals...

Read more

04 Mar 2025 14:23

News

Senores Pharma jumps on inking pact to acquire 14 ANDAs from Dr. Reddy's Labs

According to an exchange filing, the basket of acquired ANDAs consists of 13 USFDA-approve...

Read more

04 Mar 2025 15:35

SWOT Analysis Of Remus Pharmaceuticals Ltd

Strength

4

S

Weakness

3

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Remus Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Remus Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd

Which company has a larger market capitalization, Remus Pharmaceuticals Ltd or Senores Pharmaceuticals Ltd?

Market cap of Remus Pharmaceuticals Ltd is 1,300 Cr while Market cap of Senores Pharmaceuticals Ltd is 2,287 Cr

What are the key factors driving the stock performance of Remus Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd?

The stock performance of Remus Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Remus Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd?

As of May 17, 2025, the Remus Pharmaceuticals Ltd stock price is INR ₹2207.7. On the other hand, Senores Pharmaceuticals Ltd stock price is INR ₹496.7.

How do dividend payouts of Remus Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd compare?

To compare the dividend payouts of Remus Pharmaceuticals Ltd and Senores Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions